Page 2


  • Image attribution tooltip
    Jonathan Gardner / BioPharma Dive
    Image attribution tooltip

    Novartis cancels Beigene partnership as cancer drug gains EU approval

    The terminated deal leaves Novartis without a PD-1 inhibitor nine years after Merck’s Keytruda won its first approval.

  • A headshot of Kris Elverum, CEO of AIRNA.
    Image attribution tooltip
    Permission granted by AIRNA
    Image attribution tooltip

    Startup Airna emerges from stealth to bring RNA editing to a rare disease

    Airna is one of several biotechs that have set their sights on alpha-1 antitrypsin deficiency in recent years, with competitors such as AlveoGene, Wave Life Sciences and Arrowhead Pharmaceuticals.

  • Congressman Garcia gestures to a cardboard meme of two identical Spiderman characters pointing at one another.
    Image attribution tooltip
    Rebecca Pifer/BioPharma Dive
    Image attribution tooltip

    PBMs, PhRMA trade blame over drug costs in House hearing

    Pharmacy benefit manager lobby PCMA and drugmaker lobby PhRMA pointed fingers over problems in the prescription supply chain during the House committee's second hearing on the PBM industry.

  • A magnifying glass rests on a calculator atop a paper chart.
    Image attribution tooltip
    deepblue4you via Getty Images
    Image attribution tooltip

    Histogen plans to wind down operations after failing to find a partner

    All but two employees will be gone by Sept. 30 as the company seeks shareholder approval for a dissolution plan.

  • An empty laboratory
    Image attribution tooltip
    onurdongel via Getty Images
    Image attribution tooltip

    Kinnate lays off 70% of staff, reorganizes pipeline

    The company is restructuring its workforce and discontinuing programs, including its monotherapy combination of its drug exarafenib with Pfizer’s Mektovi. 

  • The front entrance of the Food And Drug Administration headquarters building.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA panel backs Alnylam drug despite doubts over benefit

    “There is a light wind for benefit, and no wind for risk,” said one adviser who voted with eight others to recommend the biotech’s drug Onpattro for cardiomyopathy of ATTR amyloidosis.

    Updated Sept. 14, 2023
  • An illustration of two lungs on a scientific background colored orange.
    Image attribution tooltip
    Mohammed Haneefa Nizamudeen via Getty Images
    Image attribution tooltip

    UK biotech AlveoGene launches with plans for inhaled gene therapy

    The company is working on a treatment of alpha-1 antitrypsin deficiency, which it claims it can deliver direct to lung cells via a nebulizer.

  • A podium showing the logo for the Centers for Disease Control and Prevention is seen.
    Image attribution tooltip
    Kevin C. Cox via Getty Images
    Image attribution tooltip

    CDC endorses new COVID boosters as focus turns to rollout

    This fall will now feature vaccination campaigns for COVID-19, influenza and respiratory syncytial virus.

  • Akili's digital therapeutic, EndeavorRx, involves navigating obstacles in different courses. It's intended to improve attention.
    Image attribution tooltip
    Courtesy of Akili Interactive
    Image attribution tooltip

    Akili cuts 40% of workforce, plans shift to non-prescription model

    The digital therapeutics company expects to extend its cash runway into 2025 with the changes.

  • A stock photo of blocks arranged to illustrate layoffs
    Image attribution tooltip
    Andrii Yalanskyi via Getty Images
    Image attribution tooltip

    2Seventy CEO Leschly to step down as company cuts staff, spending

    Citing “near-term headwinds,” the cancer cell therapy developer will lay off 176 employees and pare back spending.

  • A photo of a declining stock price.
    Image attribution tooltip
    Leonid Sorokin via Getty Images
    Image attribution tooltip
    Emerging biotech

    After IPO success, Acelyrin hits trial setback with inflammation drug

    Acelyrin’s share value collapsed Tuesday after its lead drug fell short in the company’s first big trial test since it raised $540 million in a May IPO.

  • A man in a blue suit stands for a photo.
    Image attribution tooltip
    Permission granted by Actio Bio
    Image attribution tooltip

    Actio, a precision medicine startup, launches with $55M and a mouse lab partnership

    The two-year-old San Diego biotech is allied with The Jackson Laboratory to engineer better mouse models of the rare diseases it plans to target.

  • A person in a white lab coat and gloves works in a lab.
    Image attribution tooltip
    Permission granted by Rome Therapeutics
    Image attribution tooltip
    Emerging biotech

    With latest fundraise, Rome Therapeutics works to drug the ‘dark genome’

    Johnson & Johnson and Bristol Myers Squibb have joined a group of new investors backing Rosana Kapeller’s startup, which launched in 2020 after incubating with GV.

  • Header image for "How CFOs Can Raise Financing During a Downturn"
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Bausch + Lomb seeks funding for eye drug acquisition from Novartis

    Fitch Ratings called the deal to buy the Xiidra treatment “strategically sound” even as the company’s plan for funding the deal would increase its leverage.

  • Close up of conference room with glasses of water on the table with papers, armchairs and a large window.
    Image attribution tooltip
    Igor Kutyaev via Getty Images
    Image attribution tooltip

    Ex-Sanofi executive Sibold joins Madrigal as new CEO

    Bill Sibold will replace Paul Friedman as head of the NASH drug developer as it attempts to win approval of what could be the first medicine for the liver disease. 

  • An illustration of neuron cells in abstract dark space.
    Image attribution tooltip
    whitehoune via Getty Images
    Image attribution tooltip
    Emerging biotech

    New startup Arialys takes aim at the immune system, hoping to create neuropsychiatry drugs

    Arialys Therapeutics launched Tuesday with $58 million in funding from a group of life sciences investors that includes Johnson & Johnson’s venture arm.

  • Image attribution tooltip
    Jonathan Gardner / BioPharma Dive
    Image attribution tooltip

    Daiichi Sankyo, with new data, to seek FDA approval of lung cancer drug

    The HER3-targeting treatment could become the next antibody-drug conjugate to emerge from Daiichi Sankyo’s laboratories, after the AstraZeneca-partnered Enhertu.

  • Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA approves updated COVID boosters from Pfizer, Moderna

    Pfizer and Moderna, which have seen slowing demand for their coronavirus vaccines, expect their reformulated shots will soon be available in the U.S.

  • Image attribution tooltip
    Novartis
    Image attribution tooltip

    Novartis stops work on gene therapy acquired in Gyroscope deal

    The decision follows a review by a trial monitoring committee, which concluded data for the geographic atrophy treatment didn't support further development.

  • A woman smiles at the camera.
    Image attribution tooltip
    Permission granted by Verge Genomics
    Image attribution tooltip

    AstraZeneca, seeking new drug targets, taps a genomics biotech and its AI technology

    The deal will give the pharma’s Alexion unit access to Verge Genomics’ platform, which uses human tissue data to find drug targets for diseases that degrade the nerve system.

  • Blue and red pill capsules scattered on a table
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    In advocates’ push for superbug funding, ‘$6 billion is nothing’

    The PASTEUR Act could be heading for another setback, but advocates say they see a future for funding research into antimicrobial resistance.

  • A closeup of an eye with light reflecting off of it.
    Image attribution tooltip
    Zorica Nastasic via Getty Images
    Image attribution tooltip

    Otsuka partners with Shape in deal to design eye gene therapies

    Shape uses machine learning and high throughput screening to identify new AAV capsids in ways the company’s CEO compares to the generative AI tools Midjourney and DALLE-2.

  • Roche Pharmaceutical Group's office building in Shanghai, China
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Manufacturing delays under-the-skin Tecentriq shot in US

    Roche says it won’t be able to launch the subcutaneous version of the drug until 2024 as it works with the FDA on manufacturing updates.

  • A photo of a Seattle Genetics laboratory
    Image attribution tooltip
    Permission granted by Seagen
    Image attribution tooltip

    Seagen partners with Nurix to create new kind of cancer drug

    The alliance, which aims to combine Seagen’s antibody expertise with Nurix’s targeted protein degradation research, comes as the larger biotech awaits its acquisition by Pfizer to close. 

  • Image attribution tooltip
    Alnylam Pharmaceuticals
    Image attribution tooltip

    Alnylam says hypertension drug succeeded in mid-stage study

    The trial found two higher doses of Alynlam’s RNAi therapy lowered blood pressure better than placebo. But analysts say results from a different study will be more important for the drug’s future.